Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011;Riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana en España. Cohorte CoRIS, 2011

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 30, Issue 9, 2012, Pages 517-527

  Masiá, Mar ^a   Pérez Cachafeiro, Santiago ^b   Leyes, María ^c   López Aldeguer, José ^d   López, Mariola ^e   Segura, Ferrán ^f   Blanco, José Ramón ^g   Peña, Alejandro ^h   Rodríguez, Francisco ⁱ   Vera, Mar ^j   Del Amo, Julia ^b   Gutiérrez, Félix ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g HOSPITAL SAN PEDRO   (Spain)

^h HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j CENTRO SANITARIO SANDOVAL   (Spain)

more..

Author keywords

Antiretroviral therapy; Cardiovascular; Cohort; CoRIS; Framingham; Human immunodeficiency virus (HIV); Spain

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CHOLESTEROL; DARUNAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NON NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; COCAINE DEPENDENCE; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; SMOKING; SPAIN;

ADULT; CARDIOVASCULAR DISEASES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 84868206824     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2012.02.014     Document Type: Article

References (33)

1. F. Gutiérrez, S. Padilla, M. Masiá, J.A. Iribarren, S. Moreno, and P. Viciana Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort PLoS One 1 2006 e89
2. C.M. Escolano Hortelano, J.M. Ramos Rincon, F. Gutierrez Rodero, M. Masiá Canuto, I. Hernández Aguado, and C. Benito Santaleocadia Changes in the spectrum of morbidity and mortality in hospital admissions of HIV infected patients during the HAART era Med Clin (Barc) 122 2004 1 5 (Pubitemid 38208986)
3. C. Lewden, T. May, E. Rosenthal, C. Burty, F. Bonnet, and D. Costagliola Changes in causes of death among adults infected by HIV between 2000 and 2005: The mortality 2000 and 2005 surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr 48 2008 590 598
4. M. Durand, O. Sheehy, J.G. Baril, J. Lelorier, and C.L. Tremblay Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database J Acquir Immune Defic Syndr 57 2011 245 253
5. S. Lang, M. Mary-Krause, L. Cotte, J. Gilquin, M. Partisani, and A. Simon Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population AIDS 24 2010 1228 1233
6. M. Freiberg, K. McGinnis, A. Butt, M.B. Goetz, S. Brown, and K.A. Oursler HIV is associated with clinically confirmed myocardial infarction after adjustment for smoking and other risk factors Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; March 2 Boston, Massachusetts 2011 Paper # 809
7. N. Friis-Moller, C.A. Sabin, R. Weber, A. d'Arminio Monforte, W.M. El-Sadr, and P. Reiss Combination antiretroviral therapy and the risk of myocardial infarction N Engl J Med 349 2003 1993 2003
8. A.N. Phillips, A. Carr, J. Neuhaus, F. Visnegarwala, R. Prineas, and W.J. Burman Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial Antivir Ther 13 2008 177 187 (Pubitemid 351535369)
9. M. Masiá, S. Padilla, N. García, I. Jarrin, E. Bernal, and N. López Endothelial function is impaired in HIV-infected patients with lipodystrophy Antivir Ther 15 2010 101 110
10. M. Masiá, C. Robledano, N. López, C. Escolano, and F. Gutiérrez Treatment for hepatitis C virus with pegylated interferon-{alpha} plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients J Antimicrob Chemother 66 2011 1861 1868
11. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. Macfarlane Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
12. M. Masiá, E. Bernal, S. Padilla, N. García, J.C. Escribano, and E. Martínez A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk J Antimicrob Chemother 64 2009 589 598
13. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998;19:1434-503. (Pubitemid 28470470)
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
15. H.W. Hense, H. Schulte, H. Lowel, G. Assmann, and U. Keil Framingham risk function overestimates risk of coronary heart disease in men and women from Germany: results from the MONICA Augsburg and the PROCAM cohorts Eur Heart J 24 2003 937 945 (Pubitemid 36559987)
16. J. Marrugat, P. Solana, R. D'Agostino, L. Sullivan, J. Ordovas, and F. Cordón Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada Rev Esp Cardiol 56 2003 253 261 (Pubitemid 36527246)
17. R.M. Conroy, K. Pyörälä, A.P. Fitzgerald, S. Sans, A. Menotti, and G. De Backer Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003 (Pubitemid 36712275)
18. C. Jericó, H. Knobel, M.L. Sorli, M. Montero, A. Guelar, and J. Pedro-Botet Prevalence of cardiovascular risk factors in HIV-infected patients Rev Clin Esp 206 2006 556 559 (Pubitemid 46033686)
19. M. García-Lázaro, A. Rivero Román, A. Camacho Espejo, I. Pérez-Camacho, C. Natera Kindelán, and J.J. Castón Osorio Variability in coronary risk assessment in HIV-infected patients Med Clin (Barc) 129 2007 521 524
20. E. Martinez, J.R. Arribas, J. Lopez-Aldeguer, F. Gutierrez, C. Miralles, and F. Lozano Factors associated with a high cardiovascular risk in HIV-infected patients in Spain: A multicenter, nation-wide, cross-sectional study Conference on Retroviruses and Opportunistic Infections Boston 2005 Poster 870
21. A.M. Caro-Murillo, J. Castilla, S. Pérez-Hoyos, J.M. Miró, D. Podzamczer, and R. Rubio Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results Enferm Infecc Microbiol Clin 25 2007 23 31 (Pubitemid 46232687)
22. P. Sobrino-Vegas, F. Gutiérrez, J. Berenguer, P. Labarga, F. García, and B. Alejos-Ferreras The cohort of the Spanish HIV research network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up Enferm Infecc Microbiol Clin 29 2011 645 653
23. Indicadores de calidad asistencial de GESIDA para la atención de personas infectadas por el VIH/sida Enferm Infecc Microbiol Clin 28 Suppl 5 2010 16 88
24. K.M. Anderson, P.M. Odell, P.W. Wilson, and W.B. Kannel Cardiovascular disease risk profiles Am Heart J 121 1991 293 298
25. E. Bernal, M. Masiá, S. Padilla, A. Martín-Hidalgo, and F. Gutiérrez Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort Med Clin (Barc) 128 2007 172 175 (Pubitemid 46382324)
26. M. Grau, R. Elosua, A. Cabrera de León, M.J. Guembe, J.M. Baena-Díez, and T. Vega Alonso Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study Rev Esp Cardiol 64 2011 295 304
27. M. Aboud, A. Elgalib, L. Pomeroy, G. Panayiotakopoulos, E. Skopelitis, and R. Kulasegaram Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study Int J Clin Pract 64 2010 1252 1259
28. E. Bernal, M. Masiá, S. Padilla, and F. Gutiérrez High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition AIDS Patient Care STDS 22 2008 569 575 (Pubitemid 352040053)
29. M. Masiá, E. Bernal, S. Padilla, M.L. Graells, I. Jarrin, and M.V. Almenar The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients Atherosclerosis 195 2007 167 171 (Pubitemid 47569983)
30. A.C. Ross, R. Armentrout, M.A. O'Riordan, N. Storer, N. Rizk, and D. Harrill Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy J Acquir Immune Defic Syndr 49 2008 499 506
31. L.H. Kuller, R. Tracy, W. Belloso, S. De Wit, F. Drummond, and H.C. Lane Inflammatory and coagulation biomarkers and mortality in patients with HIV infection PLoS Med 5 2008 e203
32. M. Masiá, S. Padilla, E. Bernal, M.V. Almenar, J. Molina, and I. Hernández Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients Clin Ther 29 2007 1448 1455 (Pubitemid 47354208)
33. A.C. Ross, N. Rizk, M.A. O'Riordan, V. Dogra, D. El-Bejjani, and N. Storer Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy Clin Infect Dis 49 2009 1119 1127